A Phase II Study of FOLFIRINOX Combined With the Glycogen Synthase Kinase-3 Beta (GSK-3 β) Inhibitor Elraglusib and the Transforming Growth Factor-β (TGF-β) Inhibitor Losartan in Patients With Untreated Metastatic Pancreatic Adenocarcinoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT05077800

Title field or adapter rule

{'original_value': 'A Phase II Study of FOLFIRINOX Combined With the Glycogen Synthase Kinase-3 Beta (GSK-3 β) Inhibitor Elraglusib and the Transforming Growth Factor-β (TGF-β) Inhibitor Losartan in Patients With Untreated Metastatic Pancreatic Adenocarcinoma', 'source_field': 'protocolSection.identificationModule.officialTitle'}

Ingested At

2026-10-31T23:27:26.075377+00:00

Published At

2026-09-11T00:00:00+00:00

Record Updated At

2026-09-11

Source Retrieved At

2026-10-31T22:17:56.788771+00:00

Timestamp Basis

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Date limitation

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Pancreatic Adenocarcinoma", "Pancreatic Adenocarcinoma Metastatic"]

protocolSection.statusModule.lastUpdatePostDateStruct

{"date": "2026-09-11", "type": "ACTUAL"}

protocolSection.identificationModule.nctId

"NCT05077800"

protocolSection.identificationModule.officialTitle

"A Phase II Study of FOLFIRINOX Combined With the Glycogen Synthase Kinase-3 Beta (GSK-3 \u03b2) Inhibitor Elraglusib and the Transforming Growth Factor-\u03b2 (TGF-\u03b2) Inhibitor Losartan in Patients With Untreated Metastatic Pancreatic Adenocarcinoma"

protocolSection.statusModule.overallStatus

"ACTIVE_NOT_RECRUITING"

protocolSection.designModule.phases

["PHASE2"]

protocolSection.statusModule.resultsFirstPostDateStruct

null

Study condition terms

• Pancreatic Adenocarcinoma (protocolSection.conditionsModule.conditions)
• Pancreatic Adenocarcinoma Metastatic (protocolSection.conditionsModule.conditions)

Interventions recorded in this study

• {'armGroupLabels': ['FOLFIRINOX + Elraglusib', 'FOLFIRINOX + Elraglusib + Losartan', 'FOLFIRINOX + Losartan', 'FOLFIRNINOX', 'Safety Run-In: FOLFIRINOX + Elraglusib + Losartan'], 'description': 'Combination of 4 different drugs (5-Fluorouracil (5-FU), Oxaliplatin, Irinotecan and Leucovorin) administered by intravenous infusion', 'name': 'FOLFIRNINOX', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['FOLFIRINOX + Elraglusib + Losartan', 'FOLFIRINOX + Losartan', 'Safety Run-In: FOLFIRINOX + Elraglusib + Losartan'], 'description': 'Taken Orally', 'name': 'Losartan', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['FOLFIRINOX + Elraglusib', 'FOLFIRINOX + Elraglusib + Losartan', 'Safety Run-In: FOLFIRINOX + Elraglusib + Losartan'], 'description': 'Administered by intravenous infusion', 'name': '9-ING-41', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

Drug names recorded in this source

• FOLFIRNINOX (protocolSection.armsInterventionsModule.interventions[].name)
• Losartan (protocolSection.armsInterventionsModule.interventions[].name)
• 9-ING-41 (protocolSection.armsInterventionsModule.interventions[].name)

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.